Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Increase in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 114,800 shares, an increase of 326.8% from the December 15th total of 26,900 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 129,900 shares, the days-to-cover ratio is presently 0.9 days.

Xtant Medical Price Performance

Shares of XTNT stock traded up $0.00 on Monday, hitting $0.50. The stock had a trading volume of 53,186 shares, compared to its average volume of 79,184. The company has a market capitalization of $69.51 million, a PE ratio of -3.85 and a beta of 0.34. Xtant Medical has a 52-week low of $0.33 and a 52-week high of $1.30. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%. The firm had revenue of $27.94 million during the quarter.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price objective on shares of Xtant Medical and gave the company a "buy" rating in a research report on Friday, October 18th.

Institutional Trading of Xtant Medical

An institutional investor recently bought a new position in Xtant Medical stock. Evernest Financial Advisors LLC acquired a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,000 shares of the medical device company's stock, valued at approximately $27,000. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.